Home Interviews Cyxone on the phase IIb study

Cyxone on the phase IIb study

Cyxone on the phase IIb sttudy

Cyxone on the phase IIb study

13 October, 2022

In September, biotech company Cyxone was approved by Polish authorities to start a phase IIb trial with drug candidate Rabeximod in rheumatoid arthritis. The ambition is to develop a safe treatment with a new mechanism of action in an area of significant medical need. This is a milestone for Cyxone which also will conduct the study in additional countries. Carl-Magnus Högerkorp, acting CEO, visited BioStock’s studio and talked about the approval and the trial.

Watch the interview with Cyxone’s acting CEO Carl-Magnus Högerkorp in the link below.

YouTube video




The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev